AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
=== Indigenous land claims === Belize backed the United Nations (UN) Declaration on the Rights of Indigenous Peoples in 2007, which established legal land rights to indigenous groups. Other court cases have affirmed these rights like the Supreme Court of Belize's 2013 decision to uphold its ruling in 2010 that acknowledges customary land titles as communal land for indigenous peoples. Another such case is the Caribbean Court of Justice's (CCJ) 2015 order on the Belizean government, which stipulated that the country develop a land registry to classify and exercise traditional governance over Mayan lands. Despite these rulings, Belize has made little progress to support the land rights of indigenous communities; for instance, in the two years after the CCJ's decision, Belize's government failed to launch the Mayan land registry, prompting the group to take action into its own hands. The exact ramifications of these cases need to be examined. As of 2017, Belize still struggles to recognize indigenous populations and their respective rights. According to the 50-page voluntary national report Belize created on its progress toward the UN's 2030 Sustainable Development Goals, indigenous groups are not factored into the country's indicators whatsoever. Belize's Maya population is only mentioned once in the entirety of the report.
There are more than 50 types of treatments for CTS with varied levels of evidence and recommendations across healthcare guidelines, with evidence most strongly supporting surgery, steroids, splinting for wrist positioning, and physical or occupational therapy interventions. When selecting treatment, it is important to consider the severity and chronicity of the CTS pathophysiology and to distinguish treatments that can alter the natural history of the pathophysiology (disease-modifying treatments) and treatments that only alleviate symptoms (palliative treatments). The strongest evidence for disease-modifying treatment in chronic or severe CTS cases is carpal tunnel surgery to change the shape of the carpal tunnel. The American Academy of Orthopedic Surgeons recommends proceeding conservatively with a course of nonsurgical therapies tried before release surgery is considered. A different treatment should be tried if the current treatment fails to resolve the symptoms within 2 to 7 weeks. Early surgery with carpal tunnel release is indicated where there is evidence of median nerve denervation or a person elects to proceed directly to surgical treatment. Recommendations may differ when carpal tunnel syndrome is found in association with the following conditions: diabetes mellitus, coexistent cervical radiculopathy, hypothyroidism, polyneuropathy, pregnancy, rheumatoid arthritis, and carpal tunnel syndrome in the workplace. CTS related to another pathophysiology is addressed by treating that pathology.
== Other uses == "Sip", a song from Joeboy Stranka Ivana Pernara, a Croatian political party Shelter-in-place, an emergency procedure Sip (kinship) Sip or Zip, one of the 18 months of the Haab', a part of the Maya calendric system SIP Grenade, self igniting phosphorus The Society of International Photographers, a not-for-profit organization founded in 1936 Soviet Interview Project, a research project conducted in the early 1980s Strangers in Paradise, an award-winning comic book State Implementation Plan, a United States state plan for complying with the federal Clean Air Act Sub-irrigated planter, a type of gardening container Sip as in SipSipStefan "Sip", a 2017 song by Chris Brown from Heartbreak on a Full Moon
Sources: en.wikipedia.org
On 4 June, Anvisa approved exceptional imports of Sputnik V, restricting it mainly to healthy adults and limiting it to only 1% of the population of 6 importing states, in order to manage risks through control and supervision of side effects. Anvisa said that the concern with replicating viruses has not been fully resolved, but that additional documents received indicate a substantially reduced acceptable amount. The new parameter would be in an FDA manual, which was not found. Anvisa also said that impurity and quality controls are insufficient and that the manufacturing plants must undergo corrections to meet WHO quality standards. As of 16 June, the same import conditions were extended to a total of 13 states. On 5 August, the consortium of northeastern Brazilian states, corresponding to 7 of the 13 states, suspended the import of 37 million doses due to the restrictions imposed by Anvisa. These doses will supply Mexico, Argentina and Bolivia.
== Death row conditions == A 1978 newspaper article described the death row section of the original Changi Prison as consisting of 24 cells arranged in a horse shoe shaped block around an open air grassy exercise yard. The exercise area itself was enclosed in steel bars and had a wire mesh roof to prevent escape by helicopter. Amnesty International reports that death row inmates are housed in cells of roughly three square metres (32 square feet). Walls make up three sides, while the fourth is made up of vertical bars. They are equipped with a toilet, a sleeping mat, and a bucket for washing. Exercise is permitted twice a day for half an hour at a time. Four days before the execution, the condemned is allowed to watch television or listen to the radio. Special meals of their choice are also cooked, if within the prison budget. In 1994, inmates had a budget of S$22 for their last meal. One documented last meal of an inmate was the last meal order of Tangaraju Suppiah, who asked for chicken rice, ice cream soda, nasi biryani and Milo-flavoured sweets before his hanging, while another was John Martin Scripps, who ordered a pizza and a cup of hot chocolate before his execution. Visiting rights are increased from one 20-minute visit per week to a maximum of four hours each day, though no physical contact is allowed with any visitors. In addition, two days before an execution, an inmate is allowed to have a photo shoot and be given their own clothes to pose during a photoshoot; the photo will be given to their families as remembrance.
Platelets do not need to belong to the same A-B-O blood group as the recipient or be cross-matched to ensure immune compatibility between donor and recipient unless they contain a significant amount of red blood cells (RBCs). The presence of RBCs imparts a reddish-orange color to the product and is usually associated with whole-blood platelets. Some sites may type platelets, but this is not critical. Prior to issuing platelets to the recipient, they may be irradiated to prevent transfusion-associated graft versus host disease or they may be washed to remove the plasma. The change in the recipient's platelet count after transfusion is termed the "increment" and is calculated by subtracting the pre-transfusion platelet count from the post-transfusion count. Many factors affect the increment including body size, the number of platelets transfused, and clinical features that may cause premature destruction of the transfused platelets. When recipients fail to demonstrate an adequate post-transfusion increment, this is termed platelet transfusion refractoriness. Platelets, either apheresis-derived or random-donor, can be processed through a volume reduction process. In this process, the platelets are spun in a centrifuge and plasma is removed, leaving 10 to 100 mL of platelet concentrate. Such volume-reduced platelets are normally transfused only to neonatal and pediatric patients when a large volume of plasma could overload the child's small circulatory system. The lower volume of plasma also reduces the chances of an adverse transfusion reaction to plasma proteins.
=== Choosing a support === Compatibility of support fabrics is crucial when selecting a support material. Because textiles vary so greatly careful research is necessary when making these choices. There are alternative options to fabric supports that are also important to consider. Composition, processing, structure, rigidity, and weight are all factors to consider when determining the appropriateness of a paper-based or non-textile material as a support for stabilization. The physical and chemical compatibility of textiles and long-term stability should also be evaluated for materials that will be stored in close proximity to textile artifacts.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.